Cardiovascular safety is a major concern in the development of novel medications. Tests such as affinity for ion channels or cell assays provide valuable clues but do not give a certain prediction of cardiovascular safety. Correct heart rhythm depends on the functional relationships of the complex structure of cells that initiate, distribute and deliver the precise sequence of impulses to regulate and control cardiac contraction and hence cardiac output.??
Research from the University of Strathclyde has produced an in vivo model that allows simultaneous measurement of the effect of drugs on electrocardiogram (ECG), haemodynamics and indices of cardiac contractility. Our model has been validated against standard positive and negative inotropes and can be used to monitor adverse effects of selected compounds on cardiac function.
· High fidelity prediction of cardiovascular toxicity?.
· Can be combined with complete range of cardiovascular biochemical and physiological investigations to provide information about the mechanism of potential toxicity?.
· Long term projects to select safest members from a drug development programme?.
· Development of custom assays?.
Markets and Applications
Cardiovascular safety evaluation has applications in development of novel drugs (all drug classes), vaccines, anaesthetics, diagnostic agents and medical devices?.
Contact is welcome from organisations interested in using Strathclyde University’s expertise and state-of-the art facilities in cardiovascular safety